ProMIS Neurosciences Inc. filings document a clinical-stage biotechnology issuer with common shares listed on the Nasdaq Capital Market and organized in Ontario, Canada. Formal disclosures cover PMN310 and related clinical or regulatory updates, operating results, financing arrangements, registered security status, and the company’s capital structure, including common shares, purchase warrants, pre-funded warrants, and share consolidation actions.
Proxy and 8-K filings record shareholder voting matters, director elections, independent auditor ratification, equity incentive plan proposals, board appointments, and other governance changes. The filing record also documents Nasdaq listing compliance matters, material definitive agreements, and financial condition disclosures connected to the company’s neurodegenerative-disease development programs.
ProMIS Neurosciences director and Chief Scientific Officer Neil Cashman reported an indirect purchase of 4,122 common shares at $12.13 per share through Research Capital Corporation, along with warrants to buy 4,122 additional common shares. These securities were acquired on February 3, 2026 under a Securities Purchase Agreement with selected investors.
The warrants to purchase common shares have an exercise price of $14.40 per share and are exercisable immediately. They will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from single ascending dose cohorts of PMN310. The filing also notes that common share figures reflect a one-for-twenty-five reverse split completed on November 28, 2025.
ProMIS Neurosciences Chief Development Officer Johanne Kaplan acquired equity on February 3, 2026. Kaplan bought 2,060 common shares at $12.13 per share and received warrants to purchase 2,060 additional common shares, also priced at $12.13 per common share and warrant under a Securities Purchase Agreement with selected investors.
After the transaction, Kaplan beneficially owned 2,312 common shares directly. The warrants have an exercise price of $14.40 per common share and become exercisable on February 3, 2026. They will expire on the earlier of February 3, 2031 or within 60 days after public announcement of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences Inc. insider transaction: Chief Executive Officer and director Neil K. Warma acquired 6,183 common shares of ProMIS Neurosciences Inc. on February 3, 2026 at a price of $12.13 per share. He also received warrants to purchase 6,183 common shares at an exercise price of $14.40 per share.
The warrants become exercisable on February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from PMN310 single ascending dose cohorts.
ProMIS Neurosciences principal accounting officer Max A. Milbury reported purchasing additional equity in the company. On February 3, 2026, he acquired 6,595 common shares of ProMIS Neurosciences Inc. at a purchase price of $12.13 per share under a Securities Purchase Agreement with selected investors.
He also received common share purchase warrants to buy 6,595 additional common shares. These warrants are exercisable starting February 3, 2026 and will expire on the earlier of February 3, 2031 or within 60 days after a public announcement or Form 8-K filing of topline data from cohorts treated with single ascending doses of PMN310. Following the transaction, he beneficially owned 8,409 common shares and 6,595 warrants, all held directly.
ProMIS Neurosciences director Patrick D. Kirwin reported buying additional shares and warrants in the company. On February 3, 2026, he acquired 3,050 common shares and warrants to purchase 3,050 common shares under a Securities Purchase Agreement at $12.13 per share and warrant.
Following the transaction, he directly holds 5,135 common shares and warrants for 3,050 common shares with a $14.4 exercise price. He also indirectly beneficially owns 1,653 common shares through Patrick D. Kirwin Professional Corp and 305 common shares through his spouse. The filing notes a one-for-twenty-five reverse split completed on November 28, 2025, and states the warrants expire on the earlier of February 3, 2031 or within 60 days after topline PMN310 single ascending dose data is publicly announced.
ProMIS Neurosciences Inc. large shareholder group led by Fan Yu filed an amended Schedule 13D showing updated ownership after a recent equity financing. The reporting persons collectively report beneficial ownership of 1,644,397 common shares, representing 17.0% of ProMIS’s outstanding common shares.
The filing reflects the closing of an Offering on February 3, 2026, under a Securities Purchase Agreement. Ally Bridge MedAlpha Master Fund L.P. bought 164,881 common shares and warrants for 164,881 shares for $2,000,006.53. ABG V-SIV IX Limited bought 329,760 shares and matching warrants for $3,999,988.80, and ABG V-SIV X Limited bought 206,100 shares and matching warrants for $2,499,993.
The ownership percentages are based on 8,967,693 common shares outstanding immediately after the Offering, and include both currently held shares and shares issuable upon warrant exercise subject to stated limitations. The disclosure also notes a 1-for-25 reverse stock split completed on November 28, 2025.
ProMIS Neurosciences Inc. saw a group of Ally Bridge–affiliated investors report a new insider purchase. On February 3, 2026, they acquired 700,741 Common Shares of ProMIS at $12.13 per share, bringing their indirectly beneficially owned Common Shares to 943,090.
The investors also acquired Warrants to purchase 700,741 Common Shares, with a stated exercise price of $14.40. These Warrants are exercisable immediately and will expire on the earlier of within 60 days after a defined PMN310 topline-data Milestone Event or February 3, 2031.
The Common Shares and Warrants are held across Ally Bridge MedAlpha Master Fund L.P., ABG V-SIV IX Limited and ABG V-SIV X Limited, with ABG Management Ltd., Ally Bridge Group (NY) LLC, Fan Yu and director Alex Slanix Paul reported as sharing beneficial ownership through various control relationships.
Sphera Funds Management Ltd. and related Israeli entities filed Amendment No. 3 to a Schedule 13G reporting a passive stake in ProMIS Neurosciences Inc. They report beneficial ownership of 180,697.52 common shares and warrants, representing 7.78% of the company’s common shares.
The percentage is based on approximately 2,152,444 common shares outstanding after a one-for-twenty-five reverse stock split effective as of November 28, 2025, plus 168,890 warrants currently exercisable into one common share each. The filing details positions held through Sphera Global Healthcare Master Fund and Sphera Biotech Master Fund and includes certifications that the securities are not held to change or influence control. The reporting persons also disclaim beneficial ownership and the existence of any Section 13(d) group.
ProMIS Neurosciences Inc. large shareholder Ally Bridge–related entities report beneficial ownership of 6,070,405 common shares, representing 11.3% of the company’s common shares. The shares are held with shared voting and dispositive power across ABG Management Ltd., Ally Bridge Group (NY) LLC, Ally Bridge MedAlpha Master Fund L.P. and Fan Yu.
The filing also describes a January 29, 2026 Securities Purchase Agreement under which Ally Bridge purchasers agreed to buy 700,741 common shares at $12.13 per share and receive warrants for 700,741 additional shares with a $14.40 exercise price, exercisable immediately. The warrants expire on the earlier of 60 days after a PMN310 topline data Milestone Event or February 3, 2031, with the final closing of a broader approximately $75 million offering expected on February 3, 2026. The reporting persons state they acquired their holdings for investment and may consider additional transactions or strategic actions involving ProMIS.
ProMIS Neurosciences Inc. entered into a private financing with accredited investors to raise approximately $75 million in gross proceeds through a combination of common shares and warrants. The final closing is expected on February 3, 2026.
The company agreed to sell 6,815,296 common shares, 100,000 pre-funded warrants and common share purchase warrants for 6,915,296 shares. Common shares were priced at $10.77 and $12.13 per share for certain affiliates and insiders, with warrants exercisable at $14.40. If all warrants are exercised for cash, the company may receive up to an additional approximately $100 million.